文献速递主动脉疾病

GORE EXCLUDER TAMBE 多分支内移植物治疗肾旁及胸腹主动脉瘤的解剖可行性研究

Anatomic feasibility of the investigational GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE), off-the-shelf multibranched endograft for the treatment of pararenal and thoracoabdominal aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2020-04-28

本研究回顾性分析单中心 2007 至 2017 年 227 例肾旁主动脉瘤及胸腹主动脉瘤患者的术前 CT,评估现成多分支内移植物 TAMBE 的解剖可行性。结果显示局限型(L-TAA)49% 可单用 TAMBE 治疗,而广泛型(E-TAA)仅 23% 可联合近端胸主动脉支架治疗,主动脉可行性差异显著。

要点

  • 局限型肾旁/IV 型胸腹主动脉瘤中约半数解剖上适合 TAMBE。
  • 广泛型胸腹主动脉瘤因缺乏专用锥形胸段组件,可行性仅 23%。
  • 血管入路可行性在两组均较高(79%-85%),并非主要限制因素。

核心结论

  • TAMBE 多分支内移植物理论上可用于约半数局限型肾旁及 IV 型胸腹主动脉瘤患者。
  • 广泛型胸腹主动脉瘤需联合近端胸主动脉支架,且可行性较低,需开发专用锥形胸段组件。

研究设计与样本

  • 单中心回顾性可行性研究,纳入 2007 至 2017 年接受开放或腔内修复的肾旁主动脉瘤及胸腹主动脉瘤患者。
  • 共分析 227 例退行性动脉瘤患者的术前 CT,其中广泛型(E-TAA,I-III 型)166 例,局限型(L-TAA,肾旁及 IV 型)61 例。

主要发现

  • L-TAA 组 49% 可单用 TAMBE 治疗,入路可行性 85%,主动脉可行性 74%,内脏血管可行性 72%。
  • E-TAA 组仅 23% 可联合 GORE CTAG 近端胸主动脉支架治疗,入路可行性 79%,主动脉可行性 48%,内脏血管可行性 63%。
  • 两组可行性差异主要源于主动脉可行性不同(74% vs 48%;P = .0008),与缺乏专用锥形胸段组件有关。

关键数值与推荐

  • 解剖可行性评估基于 TAMBE(含四个顺行分支端口)在制造商研究性使用说明范围内的标准。
  • 可行性分为血管入路、主动脉和内脏血管三个维度分别评估。

临床怎么用

  • 对于局限型肾旁及 IV 型胸腹主动脉瘤,TAMBE 可作为现成多分支支架的可行选择之一。
  • 广泛型胸腹主动脉瘤应用 TAMBE 需联合近端胸主动脉支架,且应充分评估主动脉解剖条件。

局限性

  • 单中心回顾性研究,样本量有限。
  • 可行性基于理论解剖评估,非实际临床结果。
  • 需与其他现成支架进行对比研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to evaluate the proportion of pararenal aortic aneurysms and thoracoabdominal aortic aneurysms (TAAAs) that could theoretically be treated with the investigational GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE; W. L. Gore & Associates, Flagstaff, Ariz) off-the-shelf multibranched endograft. METHODS: The preoperative computed tomography scans of patients with pararenal aortic aneurysms and TAAAs treated at a single institution between 2007 and 2017 were reviewed. This cohort included both open and endovascular repairs performed in either elective or urgent/emergent settings. These studies were included in a retrospective feasibility study to verify anatomic feasibility of the TAMBE graft (with four antegrade portals) employed within the manufacturer's investigational instructions for use during the U.S. pivotal trial. The patient cohort was divided into two groups: extended thoracoabdominal aneurysm (E-TAA)-extent I, II, and III TAAA; and limited pararenal and thoracoabdominal aneurysm (L-TAA)-pararenal aortic aneurysm and extent IV TAAA. The anatomic factors determining the overall theoretical feasibility were further divided into three groups: vascular access feasibility, aortic feasibility, and visceral vessel feasibility. RESULTS: Computed tomography scans of 227 patients with degenerative aneurysms were analyzed, 166 with E-TAA and 61 with L-TAA. In the L-TAA group, 49% of the cases could have been treated with the TAMBE endograft alone; access feasibility was 85%, aortic feasibility 74%, and visceral vessel feasibility 72%. In the E-TAA group, only 23% of the cases could have been treated with a TAMBE combined with a GORE CTAG proximal thoracic stent graft; access feasibility was 79%, aortic feasibility 48%, and visceral vessel feasibility 63%. The different feasibility rate was related to a difference in aortic feasibility between L-TAA and E-TAA (74% vs 48%; P = .0008) because of the lack of a dedicated tapered thoracic component. CONCLUSIONS: The TAMBE multibranched endograft can theoretically be employed in half of an all-comers cohort of patients with degenerative L-TAA. Development of a dedicated tapered thoracic component is warranted to increase the feasibility for E-TAA, and comparative studies are required to investigate differences with other available off-the-shelf stent grafts.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Cambiaghi T, Grandi A, Bilman V, et al. Anatomic feasibility of the investigational GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE), off-the-shelf multibranched endograft for the treatment of pararenal and thoracoabdominal aortic aneurysms. J Vasc Surg. 2020. PMID: 32360681. doi:10.1016/j.jvs.2020.03.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。